SECURITIES
      AND EXCHANGE COMMISSION


WASHINGTON,
      D.C. 20549








FORM
      10-QSB








xQUARTERLY
      REPORT UNDER
      SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934





For
      the
      quarterly period ended June 30, 2006





oTRANSITION
      REPORT UNDER
      SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934





For
      the
      transition period from _______________ to _________________








Commission
      file number: 000-32253





HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INC.








(Name
      of
      Small Business Issuer as specific in its Charter)





Nevada
            
            87-0650264(State
                or Other Jurisdiction of Incorporation or Organization)
            
            (I.R.S.
                Employer Identification No.)


16B/F
      Ruixin Road Bldg. No. 25 Gaoxin Road


Xi
      An
      710075 Shaanxi Province, China


(Address
      of Principal Executive Offices Including Zip Code)








Check
      whether the issuer (1) filed all reports required to be filed by Section 13
      or
      15(d) of the Exchange Act during the past 12 months (or for such shorter period
      that the registrant was required to file such reports), and (2) has been subject
      to such filing requirements for the past 90 days. xYes     oNo





The
      number of shares outstanding of the registrant's common equity as of August
      17,
      2006, was 16,466,169 shares of common stock, par value $0.018.





Transitional
      Small Business Disclosure Format (Check one): oYes      
xNo







**HUIFENG
      BIO-PHARMACEUTICAL TECHOLOGY INC.**


**AND
      SUBSIDIARIES**





**CONTENTS**







HUIFENG
                  BIO-PHARMACEUTICAL TECHOLOGY INC.AND
                  SUBSIDIARIESCONTENTS**Pages**PART
                  I. FINANCIAL INFORMATIONItem
                  I. Financial StatementsCondensed
                  Consolidated Balance Sheet as of June 30, 2006 (Unaudited)
              1Condensed
                  Consolidated Statements of Operations and Comprehensive (Loss)
                  Income for
                  the threeand
                  six months ended June 30, 2006 and 2005 (Unaudited)
              2Condensed
                  Consolidated Statements of Cash Flows for the three and six months
                  endedJune
                  30, 2006 and 2005 (Unaudited)
              3Notes
                  to Condensed Consolidated Financial Statements as of June 30, 2006
                  (Unaudited)
              4
                  -
                  8Item
                  2. Management’s Discussion and Analysis or Plan of
                  Operation
              9-13Item
                  3. Controls and Procedures
              14PART
                  II. OTHER INFORMATION
              14Item
                  1. Legal Proceedings
              14Item
                  2. Unregistered Sales of Equity Securities and Use of
                  Proceeds
              14Item
                  3. Defaults Upon Series Securities
              14Item
                  4. Submission of Matters to a Vote of Security Holders
              15Item
                  5. Other Information
              15Item
                  6. Exhibits and Reports on Form 8-K
              15SIGNATURES
              16








**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY INC.**


**AND
      SUBSIDIARIES**


**CONDENSED
      CONSOLIDATED BALANCE SHEET**


**AS
      OFJUNE 30, 2006 (UNAUDITED)**








**ASSETS****CURRENT
                  ASSETS**Cash
                  and cash equivalents
              
              $
              43,916Accounts
                  receivable, net of allowances
              
              
              1,011,761Inventories,
                  net
              
              
              1,277,383Loans
                  receivable
              
              
              437,500Due
                  from stockholders
              
              
              66,690Other
                  assets
              
              
              332,102Total
                  Current Assets
              
              
              3,169,352**PROPERTY
                  AND EQUIPMENT, NET**
              
              
              2,589,977**LAND
                  USE RIGHTS, NET**
              
              
              134,397**TOTAL
                  ASSETS**
              
              $
              5,893,726**LIABILITIES
                  AND STOCKHOLDERS' EQUITY****CURRENT
                  LIABILITIES**Accounts
                  payable
              
              $
              144,317Other
                  payables and accrued expenses
              
              
              226,882Value
                  added tax payables
              
              
              92,815Income
                  tax and other tax payables
              
              
              38,265Due
                  to stockholders
              
              
              -Total
                  Current Liabilities
              
              
              502,279**COMMITMENTS
                  AND CONTINGENCIES**
              
              
              -**MINORITY
                  INTEREST**
              
              
              459,877**STOCKHOLDERS'
                  EQUITY**Preferred
                  stock, ($0.001 par value, 5,000,000 shares
                  authorized,non
                  issued and outstanding)
              
              
              -Common
                  stock, ($0.018 par value, 100,000,000 shares authorized,16,466,169
                  shares issued and outstanding as ofJune
                  30, 2006)
              
              
              296,391Additional
                  paid-in capital
              
              
              7,256,063Retained
                  earnings (deficit)Unappropriated
              
              
              (2,816,828
              )Appropriated
              
              
              23,274Accumulated
                  other comprehensive income
              
              
              172,670Total
                  Stockholders' Equity
              
              
              5,391,447**TOTAL
                  LIABILITIES AND STOCKHOLDERS' EQUITY**
              
              $
              5,893,726




The
      accompanying notes are an integral part of these financial
      statements





1


**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY INC.**


**AND
      SUBSIDIARIES**


**CONDENSED
      CONSOLIDATED STATEMENTS OF OPERATIONS**


**AND
      COMPREHENSIVE (LOSS) INCOME (UNAUDITED)**


For
                  the Three
              
              For
                  the Three
              
              For
                  the Six
              
              For
                  the SixMonths
                  Ended
              
              Months
                  Ended
              
              Months
                  Ended
              
              Months
                  EndedJune
                  30, 2006
              
              June
                  30, 2005
              
              June
                  30, 2006
              
              June
                  30, 2005**NET
                  SALES**-
                  A
                  subsidiary
              
              $
              28,526
              
              $
              -
              
              $
              28,526
              
              $
              --
                  Third parties
              
              
              430,722
              
              
              416,274
              
              
              1,534,169
              
              
              1,342,812459,248
              
              
              416,274
              
              
              1,562,695
              
              
              1,342,812**COST
                  OF SALES**
              
              
              (357,841
              )
              
              (276,888
              )
              
              (1,291,551
              )
              
              (1,093,703
              )**GROSS
                  PROFIT**
              
              
              101,407
              
              
              139,386
              
              
              271,144
              
              
              249,109**OPERATING
                  EXPENSES**Selling
                  expenses and distribution expenses
              
              
              49,814
              
              
              32,311
              
              
              84,445
              
              
              48,705General
                  and administrative expenses
              
              
              76,185
              
              
              45,674
              
              
              110,119
              
              
              87,750Depreciation
                  and amortization
              
              
              10,787
              
              
              17,377
              
              
              22,981
              
              
              34,770Total
                  Operating Expenses
              
              
              136,786
              
              
              95,362
              
              
              217,545
              
              
              171,225**(LOSS)
                  INCOME FROM OPERATIONS**
              
              
              (35,379
              )
              
              44,024
              
              
              53,599
              
              
              77,884**OTHER
                  INCOME (EXPENSE)**Equity
                  in loss of affiliate
              
              
              -
              
              
              -
              
              
              -
              
              
              (112
              )Goodwill
                  written off
              
              
              -
              
              
              (2,764
              )
              
              -
              
              
              (2,764
              )Interest
                  income
              
              
              12,787
              
              
              7,588
              
              
              25,901
              
              
              7,637Interest
                  expense
              
              
              (26
              )
              
              -
              
              
              (57
              )
              
              -Other
                  income
              
              
              150
              
              
              -
              
              
              18,900
              
              
              42,270Total
                  Other Income, net
              
              
              12,911
              
              
              4,824
              
              
              44,744
              
              
              47,031**(LOSS)
                  INCOME FROM OPERATIONS BEFORE****TAXES
                  AND MINORITY INTEREST**
              
              
              (22,468
              )
              
              48,848
              
              
              98,343
              
              
              124,915**INCOME
                  TAX EXPENSE**
              
              
              (37,726
              )
              
              -
              
              
              (37,726
              )
              
              (25,812
              )**MINORITY
                  INTEREST**
              
              
              6,207
              
              
              3,313
              
              
              12,694
              
              
              5,396**NET
                  (LOSS) INCOME**
              
              
              (53,987
              )
              
              52,161
              
              
              73,311
              
              
              104,499**OTHER
                  COMPREHENSIVE (LOSS) INCOME**Foreign
                  currency translation (loss) gain
              
              
              (203
              )
              
              -
              
              
              97,103
              
              
              -**COMPREHENSIVE
                  (LOSS) INCOME**
              
              $
              (54,190
              )
              $
              52,161
              
              $
              170,414
              
              $
              104,499**Net
                  (loss) income per share -****basic
                  and diluted**
              
              $
              (0.003
              )
              $
              0.010
              
              $
              0.004
              
              $
              0.020Weighted
                  average number of sharesoutstanding
                  during the period -basic
                  and diluted
              
              
              16,466,169
              
              
              5,200,444
              
              
              16,466,169
              
              
              5,200,444







The
      accompanying notes are an integral part of these financial
      statements





2


**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY INC.**


**AND
      SUBSIDIARIES**


**CONDENSED
      CONSOLIDATED STATEMENTS OF CASH FLOWS**


**(UNAUDITED)**





For
                  the Six
              
              For
                  the SixMonths
                  Ended
              
              Months
                  EndedJune
                  30, 2006
              
              June
                  30,2005**CASH
                  FLOWS FROM OPERATING ACTIVITIES**Net
                  income
              
              $
              73,311
              
              $
              104,499Adjusted
                  to reconcile net income to net cash providedby
                  (used in) operating activities:Depreciation
                  and amortization - cost of sales
              
              
              110,223
              
              
              68,050Depreciation
                  and amortization
              
              
              22,980
              
              
              34,770Equity
                  in loss of affiliate
              
              
              -
              
              
              31,190Minority
                  interest
              
              
              12,694
              
              
              409,692Changes
                  in operating assets and liabilities(Increase)
                  decrease in:Accounts
                  receivable, net
              
              
              124,797
              
              
              (358,014
              )Inventories
              
              
              (351,602
              )
              
              (129,065
              )Due
                  from stockholders
              
              
              33,381
              
              
              (195,797
              )Tax
                  receivable
              
              
              -
              
              
              (13,094
              )Other
                  assets
              
              
              (40,291
              )
              
              (2,001
              )Increase
                  (decrease) in:Accounts
                  payable
              
              
              (19,555
              )
              
              32,534Other
                  payables and accrued expenses
              
              
              70,117
              
              
              (35,948
              )Value
                  added tax payable
              
              
              534
              
              
              (12,323
              )Income
                  tax and other taxes payable
              
              
              37,885
              
              
              19,103Due
                  to stockholders
              
              
              (1,250
              )
              
              (192,225
              )Net
                  cash provided by (used in) operating activities
              
              
              73,224
              
              
              (238,629
              )**CASH
                  FLOWS FROM INVESTING ACTIVITIES**Purchase
                  of property and equipment
              
              
              (114,391
              )
              
              (1,577,877
              )Net
                  cash used in investing activities
              
              
              (114,391
              )
              
              (1,577,877
              )**CASH
                  FLOWS FROM FINANCING ACTIVITIES**Registered
                  capital appropriation
              
              
              -
              
              
              2,415,458Increase
                  in loans receivable
              
              
              -
              
              
              (422,705
              )Net
                  cash provided by financing activities
              
              
              -
              
              
              1,992,753**EFFECT
                  OF EXCHANGE RATES ON CASH**
              
              
              (4,025
              )
              
              -**NET
                  (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS**
              
              
              (41,167
              )
              
              176,247**CASH
                  AND CASH EQUIVALENTS AT BEGINNING OF PERIOD**
              
              
              89,108
              
              
              167,511**CASH
                  AND CASH EQUIVALENTS AT END OF PERIOD**
              
              $
              43,916
              
              $
              343,758**SUPPLEMENTAL
                  DISCLOSURE OF CASH FLOW INFORMATION**Cash
                  paid during the year for:Income
                  taxes
              
              $
              -
              
              $
              -Interest
                  expenses
              
              $
              57
              
              $
              -





The
      accompanying notes are an integral part of these financial
      statements





3


**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY INC.**


**AND
      SUBSIDIARIES**


**NOTES
      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**


**AS
      OF JUNE 30, 2006 (UNAUDITED)**








**NOTE
      1**  **ORGANIZATION
      AND BASIS OF PRESENTATION**





Huifeng
      Bio-Pharmaceutical Technology Inc. (“Huifeng Bio-Pharmaceutical”) is a US listed
      company which was incorporated in Nevada on March 16, 2000 under the name
      Enternet, Inc. On May 23, 2002, the Articles of Incorporation were amended
      to
      change the name of the Company to Secured Data, Inc. On October 12, 2005, the
      Articles of Incorporation were amended to change the name of the Company to
      Huifeng Bio-Pharmaceutical Technology Inc.





Northwest
      Bio-Technic Inc. (“Northwest”) was incorporated in the British Virgin Islands
      (“BVI”) on June 25, 2004. Xian Huifeng Biochemistry Group Joint-Stock Company
      Limited (previously Xian Huifeng Biochemistry Joint-Stock Company Limited)
      (“Huifeng Biochemistry”) was incorporated in the People’s Republic of China
      (“PRC”) on January 20, 2000 as a company with limited liabilities and was
      restructured as a joint stock company on September 29, 2002 under the laws
      of
      the PRC. On April 20, 2005, the Articles of Incorporation were amended to change
      the name of Huifeng Biochemistry to Xian Huifeng Biochemistry Group Joint-Stock
      Company Limited.





Huifeng
      Biochemistry produces plant extracts and bio-chemical products used as
      pharmaceutical raw materials in the PRC. Most of its products are distributed
      within the PRC and some European countries.





On
      August
      23, 2001, Huifeng Biochemistry established a 70% owned subsidiary, Xian Huifeng
      Biochemistry Engineering Company Limited (“Huifeng Engineering”) in the PRC with
      a registered capital of $265,778. The subsidiary has no operations since its
      incorporation.





On
      June
      16, 2004 Huifeng Biochemistry acquired an 86.7% interest in Baoji Jisen
      Pharmaceutical Company Limited, later renamed to Xian Huifeng Pharmaceutical
      Company Limited (“Huifeng Pharmaceutical”), a limited liability company in the
      PRC. On November 10, 2004 Huifeng Pharmaceutical increased its registered
      capital from $181,159 to $603,865. The increased registered capital was fully
      subscribed by a stockholder of the Company, diluting the Company’s interest
      Huifeng Pharmaceutical from 86.7% to 26%. On May 27, 2005 the PRC Government
      approved Huifeng Biochemistry’s increased investment in Huifeng Pharmaceutical
      from $31,401 to $1,685,990 through an increase in the registered capital of
      Huifeng Pharmaceutical from $603,865 to $2,258,454. The acquisition of Huifeng
      Pharmaceutical by Huifeng Biochemistry was through a step process increasing
      Huifeng Biochemistry’s interest in Huifeng Pharmaceutical from 26% to 80.2%.





During
      2004, Huifeng Biochemistry’s stockholders exchange 100% of their ownership of
      Huifeng Biochemistry for 500,000 shares of Northwest under a reorganization
      plan. The transfer has been accounted for as a reorganization of entities under
      common control as the companies were beneficially owned by principally identical
      stockholders and share common management.





On
      December 20, 2004, pursuant to a Stock Purchase Agreement, a Huifeng
      Bio-Pharmaceutical stockholder sold 401,646 shares in Huifeng Bio-Pharmaceutical
      to two Northwest stockholders for $300,000. On the same date, Huifeng
      Bio-Pharmaceutical entered into an Agreement and Plan of Reorganization with
      the
      Stockholders of Northwest to exchange 30% of Northwest’s outstanding shares for
      4,485,311 shares of Huifeng Bio-Pharmaceutical. In addition, the Agreement
      calls
      for Huifeng Bio-Pharmaceutical to issued a Convertible Promissory Note for
      $1,900,000 that is convertible into 10,465,725 (post a one for eighteen reverse
      split) shares of Huifeng Bio-Pharmaceutical for the remaining 70% of Northwest.
      On October 12, 2005, the Company issued 10,465,725 shares of restricted common
      stock in conversion of the Convertible Promissory Note of
      $1,900,000.





The
      merger of Huifeng Bio-Pharmaceutical and Northwest has been recorded as a
      recapitalization by Northwest, with Northwest being treated as the continuing
      entity. The financial statements have been prepared as if the reorganization
      had
      occurred retroactively. Huifeng Bio-Pharmaceutical, Northwest, Huifeng
      Biochemistry, Huifeng Engineering and Huifeng Pharmaceutical are hereafter
      referred to as (“the Company”).




4


**HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY INC.**


**AND
      SUBSIDIARIES**


**NOTES
      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**


**AS
      OF JUNE 30, 2006 (UNAUDITED)**








**NOTE
      1**  **ORGANIZATION
      AND BASIS OF PRESENTATION (CONTINUED)**





Accordingly,
      the financial statements include the following:





(1)
            The
                balance sheets as of June 30, 2006 (unaudited) consist of the net
                assets
                of the acquirer at historical cost and the net assets of the acquiree
                at
                historical cost.





(2)
            The
                statements of operations for the three and six months ended June
                30, 2006
                and 2005 (unaudited) includes the operations of the acquirer for
                the
                periods presented and the operations of the acquiree from the date
                of the
                merger.





The
      accompanying unaudited condensed consolidated financial statements have been
      prepared in accordance with accounting principles generally accepted in the
      United States of America for interim financial information and pursuant to
      the
      rules and regulations of the Securities and Exchange Commission. Accordingly,
      they do not include all of the information and footnotes required by generally
      accepted accounting principles for complete financial statements.





It
      the
      opinion of management, the unaudited condensed consolidated financial statements
      contain all adjustments consisting only of normal recurring accruals considered
      necessary to present fairly the Company’s consolidated financial position at
      June 30, 2006, the consolidated results of operations for the three and six
      months ended June 30, 2006 and 2005, and consolidated cash flows for the six
      months ended June 30, 2006 and 2005. The consolidated results for the three
      and
      six months ended June 30, 2006 are not necessarily indicative of the results
      to
      be expected for the entire fiscal year ending December 31, 2006. These
      consolidated financial statements should be read in conjunction with the
      consolidated financial statements and notes for the year ended December 31,
      2005
      appearing in the Company’s annual report on Form 10-KSB as filed with the
      Securities and Exchange Commission.





**NOTE
      2**  **USE
      OF ESTIMATES**





In
      preparing financial statements in conformity with generally accepted accounting
      principles, management is required to make estimates and assumptions that affect
      the reported amounts of assets and liabilities and the disclosure of contingent
      assets and liabilities at the date of the financial statements and revenues
      and
      expenses during the reported period. Actual results could differ from those
      estimates.





**NOTE
      3**  **PRINCIPLES
      OF CONSOLIDATION**





The
      accompanying unaudited condensed consolidated financial statements as of June
      30, 2006 include the financial statements of Huifeng Bio-Pharmaceutical and
      its
      100% owned subsidiary Northwest, 100% owned subsidiary Huifeng Biochemistry,
      70%
      owned subsidiary Huifeng Engineering and 80.2% owned subsidiary Huifeng
      Pharmaceutical.





The
      accompanying unaudited condensed consolidated financial statements as of June
      30, 2005 include the financial statements of Huifeng Bio-Pharmaceutical and
      its
      100% owned subsidiary Northwest, 100% owned subsidiary Huifeng Biochemistry,
      70%
      owned subsidiary Huifeng Engineering and 80.2%
      owned subsidiary Huifeng Pharmaceutical  from
      the
      date of its step acquisition on May 27, 2005 to June 30, 2005. The Company
      accounts for its 26% investment in Huifeng Pharmaceutical from January 1, 2005
      to May 26, 2005 under the equity method of accounting.





Minority
      interest represents the minority stockholders’ proportionate share of Huifeng
      Engineering and Huifeng Pharmaceutical.





All
      significant inter-company balances and transactions have been eliminated in
      consolidation.





**NOTE
      4**  **CASH
      AND CASH EQUIVALENTS**





For
      purposes of the cash flow statements, the Company considers all highly liquid
      investments with original maturities of six months or less at the time of
      purchase to be cash equivalents .




5


**HUIFENG
        BIO-PHARMACEUTICAL TECHNOLOGY INC.**
 **AND
        SUBSIDIARIES**
 **NOTES
        TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**
 **AS
        OF JUNE 30, 2006 (UNAUDITED)**








**NOTE
      5**  **INCOME
      TAXES**





The
      Company accounts for income taxes under the Statement of Financial Accounting
      Standards No. 109, “Accounting for Income Taxes” (“Statement 109”). Under
      Statement 109, deferred tax assets and liabilities are recognized for the future
      tax consequences attributable to differences between the financial statement
      carrying amounts of existing assets and liabilities and their respective tax
      bases. Deferred tax assets and liabilities are measured using enacted tax rates
      expected to apply to taxable income in the years in which those temporary
      differences are expected to be recovered or settled. Under Statement 109, the
      effect on deferred tax assets and liabilities of a change in tax rates is
      recognized in income in the period that includes the enactment date. Huifeng
      Bio-pharmaceutical was incorporated in the United States and has incurred net
      operating loss as for income tax purposes for the six months ended June 30,
      2006
      and 2005.





Northwest,
      wholly owned subsidiary of the Company, was incorporated in the British Virgin
      Islands and, under current law of the British Virgin Islands, is not subject
      to
      tax on income or on capital gains.





Huifeng
      Biochemistry, wholly owned subsidiary of Northwest, was incorporated in the
      PRC
      being registered as a new and high technology enterprise is entitled to an
      income tax reduction. According to the document of reductions approved by the
      local tax bureau, the income tax rate was reduced from 33% to 15% on a permanent
      basis. Provision
      for income tax expenses for the six months ended June 30, 2006 and 2005 were
      $37,726 and $25,812 respectively.





Huifeng
      Engineering and Huifeng Pharmaceutical, wholly owned subsidiaries of Huifeng
      Biochemistry, were also incorporated in the PRC and subject to PRC income tax
      which is computed according to the relevant laws and regulations in the PRC.
      No
      provision for income tax expenses for the six months ended June 30, 2006 and
      2005 as Huifeng Engineering and Huifeng Pharmaceutical have incurred net
      operating loss.








**NOTE
      6**  **(LOSS)
      EARNINGS PER SHARE**





Basic
      and
      diluted net (loss) income per common share is computed based upon the weighted
      average common shares outstanding as defined by Financial Accounting Standards
      No. 128, “Earnings per Share.” As of June 30, 2006 and 2005, there were no
      common share equivalents outstanding, who’s effect was anti dilutive and not
      included in the calculation of dilutive income per share.








**NOTE
      7**  **BUSINESS
      SEGMENTS**





The
      Company operates in one segment and therefore segment information is not
      presented.








**NOTE
      8**  **RECENT
      ACCOUNTING PRONOUNCEMENTS**





SFAS
      No.
      154 (“SFAS 154”), *Accounting
      Changes and Error Corrections,* was
      issued in May 2005 and replaces APB Opinion No. 20 and SFAS No. 3 (“SFAS 3”).
      SFAS No. 154 requires retrospective application for voluntary changes in
      accounting principle in most instances and is required to be applied to all
      accounting changes made in fiscal years beginning after December 15, 2005.
      The Company’s expected April 1, 2006 adoption of SFAS No. 154 is not
      expected to have a material impact on the Company’s consolidated financial
      condition or results of operations.




6
 **HUIFENG
          BIO-PHARMACEUTICAL TECHNOLOGY INC.**
 **AND
          SUBSIDIARIES**
 **NOTES
          TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**
 **AS
          OF JUNE 30, 2006 (UNAUDITED)**


**NOTE
      8**  **RECENT
      ACCOUNTING PRONOUNCEMENTS (CONTINUED)**





In February
      2006, the FASB issued SFAS No. 155, “ *Accounting
      for Certain Hybrid Financial Instruments* ”
(SFAS
      155”), which amends SFAS No. 133, “Accounting for Derivatives Instruments and
      Hedging Activities” (“SFAS 133”) and SFAS No. 140, “ *Accounting
      for Transfers and Servicing of Financial Assets and Extinguishment of
      Liabilities* ”
(SFAS
      140”). SFAS 155 amends SFAS 133 to narrow the scope exception for interest-only
      and principal-only strips on debt instruments to include only such strips
      representing rights to receive a specified portion of the contractual interest
      or principle cash flows. SFAS 155 also amends SFAS 140 to allow qualifying
      special-purpose entities to hold a passive derivative financial instrument
      pertaining to beneficial interests that itself is a derivative instruments.
      The
      Company is currently evaluating the impact this new Standard, but believes
      that
      will not have that it will not have a material impact on the Company’s financial
      position





In
      March 2006, the FASB issued SFAS No. 156, *Accounting
      for Servicing of Financial Assets—an amendment to FASB Statement
      No. 140* (“SFAS
      156”). SFAS 156 requires that all separately recognized servicing rights be
      initially measured at fair value, if practicable. In addition, this statement
      permits an entity to choose between two measurement methods (amortization method
      or fair value measurement method) for each class of separately recognized
      servicing assets and liabilities. This new accounting standard is effective
      January 1, 2007. We do not expect the adoption of SFAS 156 to have an
      impact on our results of operations or financial condition.








**NOTE
      9**  **STOCKHOLDERS’
      EQUITY**





On
      March
      28, 2006, the Company filed an amendment to its Articles of Incorporation to
      increase the par value of its common stock from $0.000555 to
      $0.018.








**NOTE
      10**  **COMMITMENTS
      AND CONTINGENCIES**





**Commitments**




The
      Company occupies office space from a third party under an operating lease which
      expires on March 31, 2008 at a quarterly rental of $3,188. Accordingly, for
      the six
      months ended June 30, 2006 and 2005, the Company recognized rental expenses
      for
      this space in the amount of $6,376 and $6,160 respectively.





As
      of
      June 30, 2006, the Company has outstanding commitments with respect to the
      non-cancelable operating leases, which are due as follows:


2007
              
              $
              12,7502008
              
              
              9,563$
              22,313





**NOTE
      11**  **RELATED
      PARTY TRANSACTIONS**





As
      of
      June 30, 2006 and 2005, the stockholders owed the Company $66,690 and $258,290
      respectively for advances made on an unsecured basis and repayable on demand.
      Interest is charged at 6% per annum on the amount due. Total interest income
      amounted to $1,986 and $0 for the six months ended June 30, 2006 and 2005
      respectively.





As
      of
      June 30, 2006 and 2005, the Company also owed the stockholders $0 and $1,208
      respectively for advances made on an unsecured basis, free of interest payment
      and repayable on demand.





During
      the three months ended June 2006, the Company’s subsidiary - Huifeng
      Biochemistry sold finished goods to another subsidiary - Huifeng Pharmaceutical
      at the production cost totaling $28,526.




7


**HUIFENG
        BIO-PHARMACEUTICAL TECHNOLOGY INC.**
 **AND
        SUBSIDIARIES**
 **NOTES
        TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**
 **AS
        OF JUNE 30, 2006 (UNAUDITED)**


**NOTE
      12**  **CONCENTRATIONS
      AND RISKS**





During
      the six months ended June 30, 2006 and 2005, 100% of the Company’s assets were
      located in China.





During
      the six months ended June 30, 2006 and 2005, 63% and 67% of the Company’s
      revenues were derived from companies located in China respectively.







8


**Item
      2. Management's Discussion and Analysis or Plan of
      Operation.**





This
      report contains forward-looking statements within the meaning of the federal
      securities laws. These include statements about our expectations, beliefs,
      intentions or strategies for the future, which we indicate by words or phrases
      such as "anticipate," "expect," "intend," "plan," "will," "we believe," "HFGB
      believes," "management believes" and similar language. The forward-looking
      statements are based on the current expectations of HFGB and are subject to
      certain risks, uncertainties and assumptions, including those set forth in
      the
      discussion under "Management's Discussion and Analysis or Plan of Operation".
      The actual results may differ materially from results anticipated in these
      forward-looking statements. We base the forward-looking statements on
      information currently available to us, and we assume no obligation to update
      them.







On
      December 20, 2004, pursuant to the Malone Agreement, Art Malone, Jr. ("Selling
      Shareholder") sold 7,229,601 shares of the common stock of the Company for
      $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals on the closing
      date of December 20, 2004. Such 7,229,601 shares of the common stock of the
      Company represented approximately 56.18% of the total outstanding stock of
      the
      Company as of that date.




Immediately
      thereafter, pursuant to the terms of an Agreement and Plan of Reorganization
      dated December 20, 2004 ("Northwest Agreement"), the Company agreed to purchase
      all of the outstanding shares of Northwest BioTechnic, Inc. (“NBTI”), a British
      Virgin Islands corporation (the “Acquisition”). NBTI was incorporated in the
      British Virgin Islands on June 25, 2004.




At
      the
      time of the Acquisition, NBTI had a total of 500,000 shares issued and
      outstanding, 250,000 of which were held by Jing An Wang, and 50,000 each were
      held by Xinwen Hou, Zhang Jungi, Wang Bijun, Wang Zhilan, and Wang Xugang (the
      “NBTI Shareholders”). Pursuant to the terms of the Northwest Agreement, at the
      closing of the Acquisition, the Company delivered the following consideration
      to
      the NBTI Shareholders: (i) 80,735,590 newly-issued shares of the common stock
      of
      the Company (the “Initial NBTI Consideration”) in exchange for 30% of the total
      outstanding shares of NBTI (such shares of the common stock of the Company
      allocated among the NBTI Shareholders on a pro rata basis according to their
      respective ownership of NBTI); and (ii) a promissory note (the “Promissory
      Note”) payable to the NBTI Shareholders for the total amount of $1,900,000, in
      exchange for the remaining 70% of the total outstanding shares of NBTI. The
      Promissory Note is convertible into 10,465,725 shares of the Company's common
      stock (allocated among the NBTI Shareholders on a pro rata basis according
      to
      their respective ownership of NBTI), with such number of shares calculated
      assuming the completion of a one-for-eighteen reverse split of the Company’s
      common stock prior to such conversion. Based on the current ownership of NBTI
      shares by the NBTI Shareholders, Jing An Wang would receive 5,232,860 shares
      of
      the Company’s common stock upon conversion, and each of Xinwen Hou, Zhang Jungi,
      Wang Bijun, Wang Zhilan, and Wang Xugang would receive 1,046,573 shares of
      the
      Company’s common stock.




NBTI
      operates through its wholly owned subsidiary, Huifeng Biochemistry Joint Stock
      Company ("Huifeng"), which is a joint venture company established under the
      laws
      of China and is engaged in the production and sales of plant extracts,
      biochemical products and pharmaceutical raw products in the PRC.




The
      exchange was treated as a reverse acquisition for accounting purposes. As such,
      the financial information reflected activity subsequent to the acquisition
      of
      the Company and its subsidiaries and financial activity of NBTI prior to the
      acquisition. We will continue the business operations conducted by
      NBTI.




The
      Company filed a definitive Information Statement pursuant to Section 14(c)
      of
      the Securities Exchange Act of 1934 on September 13, 2005, to change the name
      of
      the Company to "Huifeng Bio-Pharmaceutical Technology Inc.". On October 12,
      2005, the name of the Company changed to Huifeng Bio-pharmaceutical Technology
      Inc. and the ticker symbol changed to HFGB.OB.




9





**CRITICAL
      ACCOUNTING POLICIES AND ESTIMATES**


We
      have
      identified one policy area as critical to the understanding of our consolidated
      financial statements. The preparation of our consolidated financial statements
      requires management to make estimates and assumptions that affect the reported
      amounts of assets and liabilities and disclosure of contingent assets and
      liabilities at the date of the consolidated financial statements and the
      reported amounts of sales and expenses during the reporting periods. With
      respect to net realizable value of the Company's accounts receivable and
      inventories, significant estimation judgments are made and actual results could
      differ materially from these estimates.





The
      Company does not have any reserves against its accounts receivable or
      inventories at June 30, 2006 and 2005. Management's estimation that there are
      no
      reserves is based on the current facts that there are no significant aged
      accounts receivable and the current inventory turnover is sufficient to realize
      the current carrying value of the inventories. In making their judgment,
      management has assumed that there will be continued demand for their products
      in
      the future, thereby maintaining adequate turnover of the inventories.
      Additionally, management has assumed that customers will continue to pay their
      outstanding invoices timely, and that their customers’ financial positions will
      not deteriorate significantly in the future, which would result in their
      inability to pay their debts to the Company. While the Company's management
      currently believes that there is little likelihood that the actual results
      of
      their current estimates will differ materially from its current estimates,
      if
      customer demand for its products decreases significantly in the near future,
      or
      if the financial position of its customers deteriorates in the near future,
      the
      Company could realize significant write downs for slow moving inventories or
      non-recoverable accounts receivable.




We
      believe the following is among the most critical accounting policies that impact
      our consolidated financial statements. We suggest that our significant
      accounting policies, as described in our consolidated financial statements
      in
      the Summary of Significant Accounting Policies, be read in conjunction with
      this
      Management's Discussion and Analysis of Financial Condition and Results of
      Operations.





We
      recognize revenue in accordance with Staff Accounting Bulletin ("SAB") No.
      104.
      All of the following criteria must exist in order for us to recognize
      revenue:





1.
      Persuasive evidence of an arrangement exists;





2.
      Delivery has occurred or services have been rendered;





3.
      The
      seller's price to the buyer is fixed or determinable; and





4.
      Recoverability is reasonably assured.





The
      majority of the Company's revenue results from sales contracts with distributors
      and revenue is generated upon the shipment of goods. The Company's pricing
      structure is fixed and there are no rebate or discount programs. Management
      conducts credit background checks for new customers as a means to reduce the
      subjectivity of assuring recoverability. Based on these factors, the Company
      believes that it can apply the provisions of SAB 104 with minimal
      subjectivity.





**RESULTS
      OF OPERATIONS**





THREE
      MONTHS ENDED JUNE 30, 2006 COMPARED TO THREE MONTHS ENDED JUNE 30,
      2005





10


Revenues,
      Cost of Revenues and Gross Margin





Revenues
      for the quarter ended June 30, 2006 were $459,248, an increase of $42,974 from
      $416,274 for the same quarter in 2005. Our increase in sales for the second
      quarter of 2006 was due to a significant increase in sales of our pharmaceutical
      material products after we received our GMP certification during February 2006,
      but was somewhat offset by a decrease in sales of pharmaceutical intermediates,
      plant extractive and other products because approximately five new competitors
      entered the market during the first quarter of 2006 as a result of additional
      media attention relating to the Company’s business in the PRC and currency
      exchange rates, as compared with the same quarter in 2005:




Product
            
            
            For
                the quarterended
              June
                30,
            
            
            Increase
                /
              (Decrease)2006
            
            
            2005Pharmaceutical
                intermediates
            
            $
            101,609
            
            $
            244,691
            
            $
            (143,082
            )Pharmaceutical
                material
            
            
            250,198
            
            
            93
            
            
            250,105Plant
                Extractive and others
            
            
            107,441
            
            
            171,490
            
            
            (64,049
            )TOTAL
            
            $
            459,248
            
            $
            416,274
            
            $
            42,974







Cost
      of
      revenues for the quarter ended June 30, 2006 were $357,841, an increase of
      $80,953 from $276,888 for the quarter ended June 30, 2005. Compared to the
      quarter ended June 30, 2005, the increase in the cost of revenues for the second
      quarter of 2006 was because of the significant increase in sales of our
      pharmaceutical material products after we received our GMP certification during
      February 2006 and a decrease in sales of pharmaceutical intermediates, plant
      extractive and others compared with the same quarter in 2005:




Product
              
              
              For
                  the quarterended
                June
                  30,
              
              
              Increase
                  /
                (Decrease)2006
              
              
              2005Pharmaceutical
                  intermediates
              
              $
              68,944
              
              $
              143,664
              
              $
              (74,720
              )Pharmaceutical
                  material
              
              
              198,538
              
              
              103
              
              
              198,435Plant
                  Extractive and others
              
              
              90,359
              
              
              133,121
              
              
              (42,762
              )TOTAL
              
              $
              357,841
              
              $
              276,888
              
              $
              80,953


Gross
      margin for the quarter ended June 30, 2006 was $101,407, a decrease of $37,979
      from $139,386 for the same period ended June 30, 2005.





Our
      gross
      profit margin for 2006 decreased from 33.5% for the second quarter of 2005
      to
      22.1% in the same quarter in 2006 because of a decrease in the selling price
      of
      pharmaceutical intermediates and plant extractives and an increase in the
      purchase cost of the raw materials including pyridine and iodine for production
      of pharmaceutical materials.





11


General
      and Administrative Expenses





General
      and Administrative expenses totaled $76,185 for the three months ended June
      30,
      2006, an increase of $30,511 from $45,674 for the three months ended June 30,
      2005. The increase in general and administrative expenses was mainly due to
      an
      increase in legal and professional fees of $21,056.





Selling
      and Distribution Expenses





Selling
      and distribution expenses totaled $49,814 for the three months ended June 30,
      2006, an increase of $17,503 from $32,311 for the three months ended June 30,
      2005. The increase in selling and distribution expenses was mainly due to an
      increase in meeting expenses of $6,344 and air transportation for overseas
      sales
      of $16,964.





SIX
      MONTHS ENDED JUNE 30, 2006 COMPARED TO SIX MONTHS ENDED JUNE 30,
      2005





Revenues,
      Cost of Revenues and Gross Margin





Revenues
      for the six months ended June 30, 2006 were $1,562,695, an increase of $219,883
      from $1,342,812 for same period in 2005. Our increase in revenues of sales
      in
      2006 was mainly attributable to the significant increase in our sales of
      pharmaceutical material products in the first six months of 2006 and a decrease
      in sales of pharmaceutical intermediates, plant extractive and other products
      against the same period in 2005:




Product
            
            Six
                months ended
              June
                30,
            Increase
                /
              (Decrease)2006
            
            
            2005Pharmaceutical
                intermediates
            
            $
            515,761
            
            $
            1,144,021
            
            $
            (628,260
            )Pharmaceutical
                material
            
            
            893,169
            
            
            227
            
            
            892,942Plant
                Extractive and others
            
            
            153,765
            
            
            198,564
            
            
            (44,799
            )TOTAL
            
            $
            1,562,695
            
            $
            1,342,812
            
            $
            219,883





Cost
      of
      revenues for the six months ended June 30, 2006 were $1,291,551, an increase
      of
      $197,848 from $1,093,703 for the six months ended June 30, 2005. The increase
      in
      cost of revenues of our products was because of our increase in sales of revenue
      in 2006 for the sales of pharmaceutical material products compared with
      2005:




Product
            
            Six
                  months ended
                June
                  30,
            
            Increase
                /
              (Decrease)2006
            
            
            2005Pharmaceutical
                intermediates
            
            $
            403,038
            
            $
            884,797
            
            $
            (481,759
            )Pharmaceutical
                material
            
            
            766,966
            
            
            206
            
            
            766,760Plant
                Extractive and others
            
            
            121,547
            
            
            208,700
            
            
            (87,153
            )TOTAL
            
            $
            1,291,551
            
            $
            1,093,703
            
            $
            197,848






12


Gross
      margin for the six months ended June 30, 2006 was $271,144, an increase of
      $22,035 from $249,109 for the period ended June 30, 2005. However, our gross
      profit margin for 2006 decreased slightly from 18.6% in the first six months
      of
      2005 to 17.3% in the same period in 2006 because the increase in the cost of
      revenues for our products was not in the same proportion as the increase in
      revenue.





General
      and Administrative Expenses





General
      and Administrative expenses totaled $110,119 for the six months ended June
      30,
      2006, an increase of $22,369 from $87,750 for the six months ended June 30,
      2005. The increase in general and administrative expenses was mainly due to
      an
      increase in legal and professional fees of $21,056 during the three months
      ended
      June 30, 2006.





Selling
      and Distribution Expenses





Selling
      and distribution expenses totaled $84,445 for the six months ended June 30,
      2006, an increase of $35,740 from $48,705 for the six months ended June 30,
      2005. The increase in selling and distribution expenses was mainly due to an
      increase in meeting expenses of $13,079 and air transportation for overseas
      sales of $27,552.





Liquidity
      and Capital Resources





Cash





Our
      cash
      balance amounted to $43,916 at June 30, 2006.





In
      the
      six months ended June 30, 2006, our cash provided by operating activities
      totaled $73,224, mainly due to our net income for the period of $73,311, a
      decrease in accounts receivable in the six month period, which totaled $124,797,
      and an increase in inventory of $351,602. Increase in inventory was as a result
      of our increase in operating scale and an emphasis on quicker collections to
      bring in more working capital, resulting in decreased accounts receivable.
      In
      the six months ended June 30, 2006, cash flow used in investing activities
      totaled $114,391.





The
      Company is currently funding its operations from our income from
      operations.





Working
      Capital





Our
      working capital amounted to $2,667,073 at June 30, 2006.





**INFLATION**





Inflation
      has not had a material impact on our business.





**CURRENCY
      EXCHANGE FLUCTUATIONS**





All
      of
      our revenues and majority of the expenses in 2005 and 2006 were denominated
      primarily in Renminbi ("RMB"), the currency of The People’s Republic of China.
      There can be no assurance that RMB/US dollar exchange rates will remain stable.
      A devaluation of RMB relative to the U.S. dollar would adversely affect our
      business, financial condition and results of operations. We do not engage in
      currency hedging. On
      July
      22, 2005, the RMB rose about 2 percent against the U.S. dollar to a new exchange
      rate of 8.11 RMB to 1 U.S. dollar. As a result of the appreciation of the RMB,
      we recognized a foreign currency translation gain of $97,103 during the first
      six months of 2006.





13


**Item
      3. Controls and Procedures**





We
      maintain disclosure controls and procedures that are designed to ensure that
      information required to be disclosed in the Company's Exchange Act reports
      is
      recorded, processed, summarized and reported within the time periods specified
      in the SEC's rules and forms, and that such information is accumulated and
      communicated to our management, including its Chief Executive Officer and Chief
      Financial Officer, as appropriate, to allow timely decisions regarding required
      disclosure based closely on the definition of "disclosure controls and
      procedures" in Rule 13a-14(c). Our disclosure controls and procedures are
      designed to provide a reasonable level of assurance of reaching our desired
      disclosure control objectives. In designing and evaluating the disclosure
      controls and procedures, our management recognized that any controls and
      procedures, no matter how well designed and operated, can provide only
      reasonable assurance of achieving the desired control objectives, and management
      necessarily was required to apply its judgment in evaluating the cost-benefit
      relationship of possible controls and procedures. Our certifying officers have
      concluded that our disclosure controls and procedures are effective in reaching
      that level of assurance.




As
      of the
      end of the period of this report, we carried out an evaluation, under the
      supervision and with the participation of our management including our Chief
      Executive Officer and our Chief Financial Officer, of the effectiveness of
      the
      design and operation of our disclosure controls and procedures. Based on the
      foregoing, our Chief Executive Officer and Chief Financial Officer concluded
      that our disclosure controls and procedures were effective.





**PART
      II. OTHER INFORMATION**








**Item
      1. Legal Proceedings:**





We
      are
      currently not involved in any litigation that we believe could have a material
      adverse effect on our financial condition or results of operations. There is
      no
      action, suit, proceeding, inquiry or investigation before or by any court,
      public board, government agency, self-regulatory organization or body pending
      or, to the knowledge of the executive officers of our Company or any of our
      subsidiaries, threatened against or affecting the Company, our common stock,
      any
      of our subsidiaries or of our Company's or our Company's subsidiaries' officers
      or directors in their capacities as such, in which an adverse decision could
      have a material adverse effect.





**Item
      2 - Unregistered Sales of Equity Securities and Use of Proceeds:**





None





**Item
      3. Defaults Upon Senior Securities:**





None




14


**Item
      4. Submission of Matters to a Vote of Security Holders:**





None





**Item
      5. Other Information:**





None







**Item
      6. Exhibits and Reports on Form 8-K**





(a)
      Exhibits





3.1.
            Articles
                of Incorporation (1)3.2
            ByLaws
                (1)3.3
            Certificate
                of Amendment to Articles of Incorporation (2)10.1
            Amended
                Agreement and Plan of Reorganization dated July 13, 2004
                (3)10.2
            Agreement
                and Plan of Reorganization dated as of December 20, 2004 by and among
                Secured Data, Inc., Northwest Bio-Technic Inc., and the shareholders
                of
                Northwest Bio- Technic Inc.; and Convertible Promissory Note
                (3)10.3.
            Amendment
                No. 1 to the Convertible Promissory Note Due June 30, 2005
                (4)31.1
            Sarbanes
                Oxley Section 302 Certification31.2
            Sarbanes
                Oxley Section 302 Certification32.1
            Sarbanes
                Oxley Section 906 Certification32.2
            Sarbanes
                Oxley Section 906 Certification99.1
            Code
                of Ethics (2)




(1)
            Incorporated
                by Reference from the registration statement on form SB-2 filed on
                or
                about July 28, 2000.




(2)
            Incorporated
                by Reference from the registrant's quarterly report on Form 10-qsb
                for the
                fiscal quarter ended March 31, 2004 filed on May 17,
                2004.





(3)
            Incorporated
                by Reference from registrant's current report on Form 8-k filed on
                August
                11, 2004.





(4)
            Incorporated
                by reference from the Current Report on Form 8-K filed on or about
                July 7,
                2005.


15





SIGNATURES





Pursuant
      to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
      1934, as amended, the registrant has duly caused this Report to be signed on
      its
      behalf by the undersigned, thereunto duly authorized this 18th day of August,
      2006.





HUIFENG
                BIO-PHARMACEUTICAL TECHNOLOGY, INC.By:
            /s/ JING
              AN
              WANGJing
                An Wang
              Chief
                Executive Officer


16